Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K2DR
|
|||
| Former ID |
DNC009638
|
|||
| Drug Name |
5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one
|
|||
| Synonyms |
CHEMBL459071; 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one; 5-(pyrid-3-yl)-2h-indolin-2-one; SCHEMBL748904; SCHEMBL6840746; LRXSVYIRRDZVNQ-UHFFFAOYSA-N; BDBM50273706; 220904-98-3
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H10N2O
|
|||
| Canonical SMILES |
C1C2=C(C=CC(=C2)C3=CN=CC=C3)NC1=O
|
|||
| InChI |
1S/C13H10N2O/c16-13-7-11-6-9(3-4-12(11)15-13)10-2-1-5-14-8-10/h1-6,8H,7H2,(H,15,16)
|
|||
| InChIKey |
LRXSVYIRRDZVNQ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aromatase (CYP19A1) | Target Info | Inhibitor | [1] |
| Steroid 11-beta-hydroxylase (CYP11B1) | Target Info | Inhibitor | [1] | |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Estradiol biosynthesis II | ||||
| Estradiol biosynthesis I | ||||
| Glucocorticoid biosynthesis | ||||
| Mineralocorticoid biosynthesis | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolic pathways | ||||
| Ovarian steroidogenesis | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Panther Pathway | Androgen/estrogene/progesterone biosynthesis | |||
| Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
| Steroidogenesis | ||||
| Reactome | Endogenous sterols | |||
| Glucocorticoid biosynthesis | ||||
| WikiPathways | Metapathway biotransformation | |||
| Tryptophan metabolism | ||||
| Oxidation by Cytochrome P450 | ||||
| Ovarian Infertility Genes | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| FSH signaling pathway | ||||
| Integrated Breast Cancer Pathway | ||||
| Phase 1 - Functionalization of compounds | ||||
| Corticotropin-releasing hormone | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.